REGENERON PHARMACEUTICALS (REGN:NASDAQ)
$762.63 24.29 (3.2898%)
Analysed REGENERON PHARMACEUTICALS (REGN:NASDAQ) News Sources
Sector Update: Healthcare Stocks Decline Late Afternoon
30-07-2026
yahoo.com
Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Highlights: Record Dupixent Sales ...
30-07-2026
yahoo.com
Regeneron (REGN) Stock Looks Cheap On Earnings Yet Mixed Elsewhere
30-07-2026
yahoo.com
Regeneron (REGN) Q2 2026 Earnings Call Transcript
31-07-2026
fool.com
Regeneron Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
31-07-2026
moby.co
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
31-07-2026
yahoo.com
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
31-07-2026
biopharmadive.com
AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.
31-07-2026
yahoo.com
Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?
31-07-2026
trefis.com
REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance
01-08-2026
yahoo.com
What is the current price of REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The current price of REGENERON PHARMACEUTICALS (REGN:NASDAQ) is $762.63.
REGENERON PHARMACEUTICALS (REGN:NASDAQ) absolute price change since previous trading day?
The absolute price change of REGENERON PHARMACEUTICALS (REGN:NASDAQ) since the previous trading day is $24.29.
REGENERON PHARMACEUTICALS (REGN:NASDAQ) percentage price change since previous trading day?
The percentage price change of REGENERON PHARMACEUTICALS (REGN:NASDAQ) since the previous trading day is 3.2898%.
What is the most recent average sentiment score for REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The most recent average sentiment score for REGENERON PHARMACEUTICALS (REGN:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The most recent sentiment for REGENERON PHARMACEUTICALS (REGN:NASDAQ) is .
SEC-8K** Filing Available For REGENERON PHARMACEUTICALS (REGN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.